» Articles » PMID: 34278852

The Crosstalk Between Long Non-Coding RNAs and Various Types of Death in Cancer Cells

Overview
Date 2021 Jul 19
PMID 34278852
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

With the increasing aging population, cancer has become one of the leading causes of death worldwide, and the number of cancer cases and deaths is only anticipated to grow further. Long non-coding RNAs (lncRNAs), which are closely associated with the expression level of downstream genes and various types of bioactivity, are regarded as one of the key regulators of cancer cell proliferation and death. Cell death, including apoptosis, necrosis, autophagy, pyroptosis, and ferroptosis, plays a vital role in the progression of cancer. A better understanding of the regulatory relationships between lncRNAs and these various types of cancer cell death is therefore urgently required. The occurrence and development of tumors can be controlled by increasing or decreasing the expression of lncRNAs, a method which confers broad prospects for cancer treatment. Therefore, it is urgent for us to understand the influence of lncRNAs on the development of different modes of tumor death, and to evaluate whether lncRNAs have the potential to be used as biological targets for inducing cell death and predicting prognosis and recurrence of chemotherapy. The purpose of this review is to provide an overview of the various forms of cancer cell death, including apoptosis, necrosis, autophagy, pyroptosis, and ferroptosis, and to describe the mechanisms of different types of cancer cell death that are regulated by lncRNAs in order to explore potential targets for cancer therapy.

Citing Articles

Ferroptosis contributes to diabetes-induced visual pathway neuronal damage via iron accumulation and GPX4 inactivation.

Wang B, Jin Y, OuYang X, Zhu R, Wang X, Li S Metab Brain Dis. 2024; 39(7):1459-1468.

PMID: 39080199 PMC: 11513717. DOI: 10.1007/s11011-024-01398-5.


An Overview of the Immune Modulatory Properties of Long Non-Coding RNAs and Their Potential Use as Therapeutic Targets in Cancer.

Martinez-Castillo M, Elsayed A, Lopez-Berestein G, Amero P, Rodriguez-Aguayo C Noncoding RNA. 2023; 9(6).

PMID: 37987366 PMC: 10660772. DOI: 10.3390/ncrna9060070.


Ferroptosis in tumors and its relationship to other programmed cell death: role of non-coding RNAs.

Zhang Q, Fan X, Zhang X, Ju S J Transl Med. 2023; 21(1):514.

PMID: 37516888 PMC: 10387214. DOI: 10.1186/s12967-023-04370-6.


Genome-wide Exploration of a Pyroptosis-Related Long Non-Coding RNA Signature Associated With the Prognosis and Immune Response in Patients With Bladder Cancer.

Gao X, Cai J Front Genet. 2022; 13:865204.

PMID: 35571063 PMC: 9091201. DOI: 10.3389/fgene.2022.865204.


A Novel Ferroptosis-Related lncRNA Prognostic Model and Immune Infiltration Features in Skin Cutaneous Melanoma.

Sun S, Zhang G, Zhang L Front Cell Dev Biol. 2022; 9:790047.

PMID: 35186949 PMC: 8851039. DOI: 10.3389/fcell.2021.790047.

References
1.
Dobre E, Dinescu S, Costache M . Connecting the Missing Dots: ncRNAs as Critical Regulators of Therapeutic Susceptibility in Breast Cancer. Cancers (Basel). 2020; 12(9). PMC: 7565380. DOI: 10.3390/cancers12092698. View

2.
Li X, Jin F, Li Y . A novel autophagy-related lncRNA prognostic risk model for breast cancer. J Cell Mol Med. 2020; 25(1):4-14. PMC: 7810925. DOI: 10.1111/jcmm.15980. View

3.
Zheng Y, Lv P, Wang S, Cai Q, Zhang B, Huo F . LncRNA PLAC2 upregulates p53 to induce hepatocellular carcinoma cell apoptosis. Gene. 2019; 712:143944. DOI: 10.1016/j.gene.2019.143944. View

4.
Liu L, Zhou X, Zhang J, Wang G, He J, Chen Y . LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway. Eur Rev Med Pharmacol Sci. 2018; 22(24):8722-8730. DOI: 10.26355/eurrev_201812_16637. View

5.
Huang W, Huang F, Lei Z, Luo H . LncRNA SNHG11 Promotes Proliferation, Migration, Apoptosis, and Autophagy by Regulating hsa-miR-184/AGO2 in HCC. Onco Targets Ther. 2020; 13:413-421. PMC: 6969695. DOI: 10.2147/OTT.S237161. View